- Current report filing (8-K)
February 27 2009 - 5:13PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date of
Report (Date of earliest event reported): February 24,
2009
Arno
Therapeutics, Inc.
(Exact
name of registrant as specified in its charter)
Delaware
|
000-52153
|
52-2286452
|
(State
or other jurisdiction of incorporation)
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
4
Campus Drive, 2
nd
Floor, Parsippany, NJ
|
07054
|
(Address
of principal executive offices)
|
(Zip
Code)
|
(862)
703-7170
(Registrant's
telephone number, including area code)
N/A
(Former
name or former address, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
¨
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
¨
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
¨
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
¨
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item 5.02
|
Departure
of Directors or Certain Officers; Election of Directors; Appointment of
Certain Officers; Compensatory Arrangements of Certain
Officers.
|
Pursuant to the employment agreement
dated June 1, 2007, between Arno Therapeutics, Inc. (the “Company”) and Scott Z.
Fields, M.D., the Company’s President and Chief Medical Officer, the term of Dr.
Field’s employment with the Company expires on May 31, 2009. On
February 24, 2009, Dr. Fields notified the Company that he does not intend to
continue his employment beyond May 31, 2009. Dr. Fields has informed
the Company that he intends to devote more time for clinical practice following
his employment with the Company.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
Arno
Therapeutics, Inc.
|
|
|
|
|
|
Date:
February 27, 2009
|
By:
|
/s/
Brian
Lenz
|
|
|
|
Brian
Lenz
|
|
|
|
Chief
Financial Officer
|
|
|
|
|
|
Arno Therapeutics (CE) (USOTC:ARNI)
Historical Stock Chart
From May 2024 to Jun 2024
Arno Therapeutics (CE) (USOTC:ARNI)
Historical Stock Chart
From Jun 2023 to Jun 2024